Jump to Main Content
Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
- Kim, Jean, Kudisch, Max, da Silva, Nina Rosa Konichi, Asada, Hiroyuki, Aya-Shibuya, Eri, Bloomer, Michele M., Mudumba, Sri, Bhisitkul, Robert B., Desai, Tejal A.
- Journal of controlled release 2018 v.269 pp. 45-51
- blindness, drugs, eyes, glaucoma, hydrolysis, patient compliance, pharmacokinetics, rabbits
- Long-term treatment of glaucoma, a major leading cause of blindness, is challenging due to poor patient compliance. Therefore, a drug delivery device that can achieve drug release over several months can be highly beneficial for glaucoma management. Here, we evaluate the long-term pharmacokinetics and therapeutic efficacy of polycaprolactone intracameral drug delivery devices in rabbit eyes. Our study showed that a single drug delivery device loaded with a proprietary hypotensive agent, DE-117, reduced intraocular pressure in normotensive rabbits significantly for 23weeks. In addition, we demonstrated that concentration of DE-117 and its hydrolyzed active form (hDE-117) was maintained in the aqueous humor and the target tissue (iris-ciliary body) up to 24weeks. Our proof-of-concept glaucoma implant shows potential as a long-term treatment that circumvents patient compliance barriers compared to current treatment via eye drops.